PubMed
Kisspeptin signaling in reproductive biology
Pinilla L, Aguilar E, Dieguez C, et al. Physiol Rev. 2012
Compare
Kisspeptin vs Retatrutide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Kisspeptin
29 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 4% · Unfavorable overall 93%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Libido
150
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 100–1000 mcg
100–200
46
200–400
102
400–600
1
600–1000
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 78% said they felt similar to their last entry, 22% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 160 days · Based on 23 repeat reporters
Retatrutide
125 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 99% · Mixed 1% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
222
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
5
0.1–0.2 mg
3
0.2–0.4 mg
6
0.4–0.6 mg
10
0.6–1 mg
5
1–2 mg
80
2–3 mg
35
3–5 mg
17
5+ mg
61
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 51 days · Based on 45 repeat reporters
Sources (11)
Published sources linked on the Kisspeptin and Retatrutide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Kisspeptin in the control of reproduction
Skorupskaite K, George JT, Anderson RA. Fertil Steril. 2018
- Wiki study page →Source
ClinicalTrials.gov
Kisspeptin studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Pubertal development and regulation
Abreu AP, Kaiser UB. The lancet. Diabetes & endocrinology. 2016
- Wiki study page →Source
PubMed
Kisspeptin and fertility
Hameed S, Jayasena CN, Dhillo WS. The Journal of endocrinology. 2011
- Wiki study page →Source
PubMed
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
ClinicalTrials.gov
Retatrutide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. The New England journal of medicine. 2023
- Wiki study page →Source
PubMed
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi V, Koutsopoulos G, Fragoulis C, et al. Biomolecules. 2025